Keith Murphy discusses his project that uses brain organoids the explore the effect of cocaine exposure in utero.
Zacks Small Cap Research on MSN7h
RVPH: Year-End OLE UpdateRVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14th, 2024, Reviva Pharmaceutical ...
No approved drug in the U.S. has been able to fully address these symptoms. While second generation antipsychotics offer ...
Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced working memory, as seen in mental health conditions ...
Fampridine, used for improving walking in multiple sclerosis, may also enhance working memory in individuals with schizophrenia or depression.
Researchers explain how a drug that helps patients with neurological issues walk may also provide a surprising boost for the ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...
"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...
The FDA's REMS program has been found to have unintentionally created barriers to accessing clozapine, a crucial ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback